AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 302 min read$IONS

O'NEIL PATRICK R. sold $246K of IONS

O'NEIL PATRICK R. (EVP CLO & General Counsel) sold 3,069 shares of IONIS PHARMACEUTICALS INC (IONS) at $80.00 ($0.25M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'NEIL PATRICK R.
Published Jun 30, 2026, 9:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IONS
Neutral
high confidence
Mentioned
$IONS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

The disclosure updates the insider’s holdings (61,470 shares after sale) but does not introduce new company-specific fundamentals (no guidance, trial, or regulatory updates).

02

Market read

Traders may note insider selling as a sentiment datapoint, but the planned nature and lack of new fundamentals keep impact limited.

03

What to watch

The article provides only the sale details; it does not include any concurrent buys, option exercises, or changes in company outlook that would strengthen a directional thesis.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-30)

Background

This is an SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals (IONS) by Patrick R. O’Neil, EVP CLO & General Counsel.

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals disclosed an EVP/general counsel open-market sale of 3,069 shares at $80/share under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is a scheduled open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

Sector

Minimal read-through for biotech/pharma sector; this is a single-officer transaction without new clinical/regulatory catalysts.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely planned liquidity management and may not reflect negative expectations.

Key entities

  • issuer
    IONIS PHARMACEUTICALS INC

    Company whose insider transaction was reported on Form 4.

  • insider
    O'NEIL PATRICK R.

    EVP CLO & General Counsel who sold shares under a pre-arranged 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$IONSMedAI 8/10

Ionis (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals (IONS) reported Q2 2026 total revenue of $268 million, up 56% excluding a one-time Sapablursen payment. Commercial revenue was $119 million, driven by DAWNZERA sales of $26 million (+63% QoQ). 2026 guidance: $875 million to $900 million revenue and non-GAAP operating loss of $425 million to $475 million. Cash was $2.1 billion.

aol.com7 min
JUL 30
$IONSMed

Ionis Pharmaceuticals: Q2 Earnings Snapshot

Ionis Pharmaceuticals (IONS) reported a Q2 loss of $115 million, or 69 cents per share. Adjusted for stock option expense, the loss was 43 cents per share. Revenue was $268 million, above Street expectations of $190.7 million, according to Zacks.

aol.com2 min
JUL 29
$IONSMedAI 8/10

IONIS PHARMACEUTICALS INC (IONS): Results of Operations and Financial Condition

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078953_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2026 financial results and highlights progress on key programs - TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large p

SEC EDGAR 8-K6 min
JUL 25
$IONSMed

Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?

Ionis Pharmaceuticals (IONS) said its late-stage CARDIO TTRansform trial of eplontersen with AstraZeneca did not meet the primary efficacy endpoint, prompting a sharp share drop and a shareholder investigation. The stock was down 26.1% over 30 days and 29.0% YTD. The article cites a $92 fair value versus $56.55 last close and discusses valuation metrics including P/S 8.8x.

simplywall.st5 min
JUL 23
$IONSMed

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

Ionis Pharmaceuticals (NASDAQ: IONS) shares fell about 23% on July 9, 2026 after it and AstraZeneca reported the Phase 3 CARDIO-TTRansform trial of eplontersen for ATTR-CM did not meet the primary efficacy endpoint. The company said adding eplontersen was not statistically beneficial in a contemporary standard-of-care population. Hagens Berman opened an investor-fraud investigation into trial transparency.

prnewswire.com3 min